Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease

Table 2 Cardio-metabolic risk factors

Risk factors	Cut-off values
BMI	BMI > 25 kg/m2 (23 in Asia) or waist circumference > 94 cm (males)/ > 80 cm (females) or ethnicity-adjusted
Fasting serum glucose	Fasting serum glucose ≥ 5.6 mmol/L (100 mg/dL) or 2-h post-load glucose levels ≥ 7.8 mmol/L (≥ 140 mg/dL) or HbA1c ≥ 5.7% (39 mmol/L) or T2DM or treatment for T2DM
Blood pressure	Blood pressure 130/85 mmHg or specific antihypertensive drug treatment
Plasma triglycerides	Plasma triglycerides ≥ 1.70 mmol/L (≥ 150 mg/dL) or lipid lowering treatment
Plasma HDL cholesterol	Plasma HDL cholesterol ≤ 1.0 mmol/L (≤ 40 mg/dL) (males) and ≤ 1.3 mmol/L (≤ 50 mg/dL) (females) or lipid lowering treatment

BMI: Body mass index; T2DM: Type 2 diabetes mellitus; HDL: High-density lipoproteins.